NCT04378075Phase 2, phase 3Terminated

A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

Study sponsor: PTC Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-03-18Actual
Enrollment · participants68Actual
Source updated2026-03-31Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures per 28 Days. After: Measure: Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures Per 28 Days During the Double-blind Period.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview